Covance Receives MHRA Accreditation for UK Facility
July 30, 2009, Princeton, NJ
The Medicines and Healthcare products Regulatory Agency (MHRA) awarded Covance's (Princeton, NJ) clinical research unit in Leeds, UK, where the company conducts first-in-human studies, with standard and supplementary accreditation for the conduct of clinical pharmacology in Europe. The MHRA accreditation, which is voluntary, ensures that research facilities and studies meet industry standards for patient safety in early clinical development.
"Covance delivers the highest level of data quality and safety for first-in-human trials, which is confirmed by the accreditation," said Rob Aspbury, MD, Covance's managing director of clinical research services, in a press release.
In order to receive this type of accreditation, formal inspections are performed by MHRA, which is based in London.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
